Interstitial Lung Disease Clinical Trials

77 recruiting

Interstitial Lung Disease Trials at a Glance

111 actively recruiting trials for interstitial lung disease are listed on ClinicalTrialsFinder across 6 cities in 39 countries. The largest study group is Not Applicable with 24 trials, with the heaviest enrollment activity in New York, Chicago, and Houston. Lead sponsors running interstitial lung disease studies include Bastiaan Driehuys, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, and United Therapeutics.

Browse interstitial lung disease trials by phase

Treatments under study

About Interstitial Lung Disease Clinical Trials

Looking for clinical trials for Interstitial Lung Disease? There are currently 77 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Interstitial Lung Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Interstitial Lung Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 111 trials

Recruiting

dEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasound

Rheumatoid ArthritisInterstitial Lung DiseaseThoracic Ultrasound+1 more
University Hospital, Tours280 enrolled1 locationNCT06235645
Recruiting
Phase 3

A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases

Interstitial Lung DiseasesSystemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim400 enrolled158 locationsNCT06806592
Recruiting

Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease

Rheumatoid ArthritisInterstitial Lung Disease
University of Colorado, Denver750 enrolled1 locationNCT03297775
Recruiting
Phase 3

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

Interstitial Lung DiseasesFamilial Pulmonary FibrosisInterstitial Lung Abnormalities
Boehringer Ingelheim80 enrolled56 locationsNCT07201922
Recruiting

Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)

Interstitial Lung Disease
Mayo Clinic635 enrolled1 locationNCT03478826
Recruiting

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Interstitial Lung DiseasePulmonary HypertensionPulmonary Hypertension Due to Lung Diseases and Hypoxia
United Therapeutics900 enrolled62 locationsNCT06388421
Recruiting
Phase 2

Efficacy of L-menthol on Breathlessness in Interstitial Lung Disease

Interstitial Lung Disease (ILD)
Region Skane20 enrolled2 locationsNCT07398287
Recruiting
Phase 3

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Progressive Pulmonary FibrosisInterstitial Lung Disease
United Therapeutics698 enrolled152 locationsNCT05943535
Recruiting
Phase 2

A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
Sunshine Lake Pharma Co., Ltd.110 enrolled1 locationNCT05139719
Recruiting
Phase 2

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

Cardiovascular DiseasesFibrosisLung Diseases+3 more
Pulmovant, Inc.20 enrolled1 locationNCT07333183
Recruiting
Phase 2

Collagen-targeted PET Imaging for Early Interstitial Lung Disease

Interstitial Lung Disease
Massachusetts General Hospital30 enrolled1 locationNCT05417776
Recruiting
Phase 1Phase 2

Feasibility of Semaglutide in Advanced Lung Disease

ObesityChronic Obstructive Pulmonary DiseaseInterstitial Lung Disease+2 more
University of Pennsylvania8 enrolled1 locationNCT05746039
Recruiting
Not Applicable

Early Recognition of Progressive Lung Fibrosis in Systemic Rheumatic Diseases

Interstitial Lung DiseaseConnective Tissue Diseases
Fondazione Policlinico Universitario Agostino Gemelli IRCCS200 enrolled1 locationNCT07541638
Recruiting
Phase 3

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Interstitial Lung DiseasePulmonary Hypertension
Insmed Incorporated344 enrolled68 locationsNCT07179380
Recruiting
Phase 3

Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease

Interstitial Lung DiseaseSystemic Sclerosis
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland86 enrolled1 locationNCT06297096
Recruiting
Not Applicable

Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial

Interstitial Lung Disease (ILD)
Hospital de Granollers152 enrolled1 locationNCT07486206
Recruiting
Not Applicable

Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial

Interstitial Lung Disease (ILD)Suspected Interstitial Lung Disease
Hospital de Granollers92 enrolled1 locationNCT07482917
Recruiting
Phase 2

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

Progressive Pulmonary FibrosisInterstitial Lung DiseasePulmonary Fibrosis+4 more
Avalyn Pharma Inc.375 enrolled152 locationsNCT06329401
Recruiting
Not Applicable

Robotic-Assisted Versus Conventional Bronchoscopy for Cryobiopsy in the Diagnosis of Interstitial Lung Disease

Lung BiopsyInterstitial Lung Disease (ILD)
University of Zurich30 enrolled2 locationsNCT07500818
Recruiting

Magnetic Resonance Imaging of the Lung: Non-Oncological Applications

Interstitial Lung Disease
Fondazione IRCCS Policlinico San Matteo di Pavia50 enrolled1 locationNCT07493187